These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 8692279)
21. The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells. Kudlacek O; Just H; Korkhov VM; Vartian N; Klinger M; Pankevych H; Yang Q; Nanoff C; Freissmuth M; Boehm S Neuropsychopharmacology; 2003 Jul; 28(7):1317-27. PubMed ID: 12784121 [TBL] [Abstract][Full Text] [Related]
24. Involvement of P1 receptors in the effect of forskolin on cyclic AMP accumulation and export in PC12 cells. Florio C; Frausin F; Vertua R; Gaion RM Biochem Pharmacol; 1999 Feb; 57(4):355-64. PubMed ID: 9933023 [TBL] [Abstract][Full Text] [Related]
25. Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes. Zocchi C; Ongini E; Ferrara S; Baraldi PG; Dionisotti S Br J Pharmacol; 1996 Apr; 117(7):1381-6. PubMed ID: 8730729 [TBL] [Abstract][Full Text] [Related]
26. Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells. Suh BC; Kim TD; Lee JU; Seong JK; Kim KT Br J Pharmacol; 2001 Sep; 134(1):132-42. PubMed ID: 11522605 [TBL] [Abstract][Full Text] [Related]
27. Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors. Cunha RA; Johansson B; Constantino MD; Sebastião AM; Fredholm BB Naunyn Schmiedebergs Arch Pharmacol; 1996 Feb; 353(3):261-71. PubMed ID: 8692280 [TBL] [Abstract][Full Text] [Related]
28. Activation of phosphodiesterase IV during desensitization of the A2A adenosine receptor-mediated cyclic AMP response in rat pheochromocytoma (PC12) cells. Chang YH; Conti M; Lee YC; Lai HL; Ching YH; Chern Y J Neurochem; 1997 Sep; 69(3):1300-9. PubMed ID: 9282956 [TBL] [Abstract][Full Text] [Related]
29. Adenosine A 2B receptors modulate cAMP levels and induce CREB but not ERK1/2 and p38 phosphorylation in rat skeletal muscle cells. Lynge J; Schulte G; Nordsborg N; Fredholm BB; Hellsten Y Biochem Biophys Res Commun; 2003 Jul; 307(1):180-7. PubMed ID: 12849998 [TBL] [Abstract][Full Text] [Related]
30. Adenosine receptor-induced cyclic AMP generation and inhibition of 5-hydroxytryptamine release in human platelets. Cooper JA; Hill SJ; Alexander SP; Rubin PC; Horn EH Br J Clin Pharmacol; 1995 Jul; 40(1):43-50. PubMed ID: 8527267 [TBL] [Abstract][Full Text] [Related]
31. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. Link AA; Kino T; Worth JA; McGuire JL; Crane ML; Chrousos GP; Wilder RL; Elenkov IJ J Immunol; 2000 Jan; 164(1):436-42. PubMed ID: 10605040 [TBL] [Abstract][Full Text] [Related]
32. Adenosine A1 receptor-mediated inhibition of cyclic AMP accumulation in type-2 but not type-1 rat astrocytes. Peakman MC; Hill SJ Eur J Pharmacol; 1996 Jun; 306(1-3):281-9. PubMed ID: 8813642 [TBL] [Abstract][Full Text] [Related]
33. A2a/D2 receptor interactions are not observed in COS-7 cells transiently transfected with dopamine D2 and adenosine A2a receptor cDNA. Snaprud P; Gerwins P; Caron MG; Libert F; Persson H; Fredholm BB; Fuxe K Biochem Pharmacol; 1994 Nov; 48(11):2043-7. PubMed ID: 7802693 [TBL] [Abstract][Full Text] [Related]
34. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. Gao Z; Li Z; Baker SP; Lasley RD; Meyer S; Elzein E; Palle V; Zablocki JA; Blackburn B; Belardinelli L J Pharmacol Exp Ther; 2001 Jul; 298(1):209-18. PubMed ID: 11408544 [TBL] [Abstract][Full Text] [Related]
35. Functional and molecular characterization of receptor subtypes mediating coronary microvascular dilation to adenosine. Hein TW; Wang W; Zoghi B; Muthuchamy M; Kuo L J Mol Cell Cardiol; 2001 Feb; 33(2):271-82. PubMed ID: 11162132 [TBL] [Abstract][Full Text] [Related]
36. Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. Kim YC; de Zwart M; Chang L; Moro S; von Frijtag Drabbe Künzel JK; Melman N; IJzerman AP; Jacobson KA J Med Chem; 1998 Jul; 41(15):2835-45. PubMed ID: 9667972 [TBL] [Abstract][Full Text] [Related]
37. Adenosine A2A receptor agonists inhibit lipopolysaccharide-induced production of tumor necrosis factor-alpha by equine monocytes. Sun WC; Moore JN; Hurley DJ; Vandenplas ML; Linden J; Cao Z; Murray TF Vet Immunol Immunopathol; 2008 Jan; 121(1-2):91-100. PubMed ID: 17913243 [TBL] [Abstract][Full Text] [Related]
38. Role of cysteine residues of rat A2a adenosine receptors in agonist binding. Mazzoni MR; Giusti L; Rossi E; Taddei S; Lucacchini A Biochim Biophys Acta; 1997 Feb; 1324(1):159-70. PubMed ID: 9059509 [TBL] [Abstract][Full Text] [Related]
39. A1 adenosine receptor inhibition of cyclic AMP formation and radioligand binding in the guinea-pig cerebral cortex. Alexander SP; Curtis AR; Kendall DA; Hill SJ Br J Pharmacol; 1994 Dec; 113(4):1501-7. PubMed ID: 7889308 [TBL] [Abstract][Full Text] [Related]
40. Characterization of the adenosine receptor in microvascular coronary endothelial cells. Schiele JO; Schwabe U Eur J Pharmacol; 1994 Sep; 269(1):51-8. PubMed ID: 7828658 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]